6 completed, 1 not yet recruiting, 1 recruiting. 3 Early Phase 1, 2 Not applicable, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Completed 3 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Safety After Oral Intake: new trials by email Literature Review of Safety After Oral Intake trials Research Report on Safety After Oral Intake
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants MDI-2517 800mg, Placebo, MDI-2517 1600mg - Safety After Oral Intake | Phase 1 | Completed | MDI Therapeutics, Inc. | 32 | 2025-11-04 | 2026-05-22 |
| Effects of Energy Drinks on Cardiovascular Endpoints Energy Drink A + Placebo Capsule, Placebo Drink + Moxifloxacin Capsule, Placebo Drink + Caffeine Capsule - Healthy Volunteers, Safety After Oral Intake | Phase 4 | Recruiting | University of the Pacific | 3 | 2025-11-01 | 2025-11-26 |
| A Research Study to Evaluate BLX-7006 in Healthy Adults BLX-7006, Placebo - Normal Healthy Volunteer, Safety After Oral Intake | Phase 1 | Not yet recruiting | Biolexis Therapeutics | 76 | 2025-09-01 | 2025-08-24 |
| Chrysin Bioavailability and Safety LipoMicel Chrysin, Non-Micellar Chrysin, Standard/Unformulated Chrysin - Bioavailability and Pharmacokinetics, Safety After Oral Intake | Not applicable | Completed | Isura | 18 | 2024-12-05 | 2025-07-15 |
| Comparison of Curcumin Bioavailability Native turmeric extract, Native turmeric extract with 7-9% volatile turmeric oils, Turmeric extract plus mixture of phytochemicals - Safety After Oral Intake, Pharmacokinetics After Oral Intake | Not applicable | Completed | University of Hohenheim | 12 | 2018-06-07 | 2019-01-10 |
| Absorption and Excretion Kinetics of the Bioactive Ingredients of Rice Bran Extract Rice bran extract, Porridge in water, Porridge in milk - Safety After Oral Intake, Pharmacokinetics After Oral Intake | Early Phase 1 | Completed | University of Hohenheim | 12 | 2016-04-01 | 2017-05-03 |
| Oral Bioavailability and Bioactivity of Prenylflavonoids From Hops Placebo, 6-prenylnaringenin, 8-prenylnaringenin - Safety After Oral Intake, Pharmacokinetics After Oral Intake | Early Phase 1 | Completed | University of Hohenheim | 16 | 2016-01-01 | 2018-03-30 |
| Bioavailability of Resveratrol From Vineatrol30 Extract Incorporated Into Micelles Vineatrol 30 native powder, Vineatrol 30 micelles - Safety After Oral Intake, Pharmacokinetics After Oral Intake | Early Phase 1 | Completed | University of Hohenheim | 12 | 2015-03-01 | 2017-05-03 |
Diabetes Mellitus, Type 2 (1) · Metabolic Diseases (1) · Obesity (1)
Body Weight (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Overweight (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
6-prenylnaringenin (1) · 8-prenylnaringenin (1) · Caffeine (1) · Control Groups (1) · Milk (1) · Moxifloxacin (1) · Rice Bran Oil (1) · Taurine (1) · Water (1) · turmeric extract (1)
University of Hohenheim (4) · Biolexis Therapeutics (1) · Isura (1) · MDI Therapeutics, Inc. (1) · University of the Pacific (1)
Germany (4) · United States (2) · Australia (1) · Canada (1)
Jan Frank, Prof. Dr (2) · Jan Frank, Prof. Dr. (2) · Christian Busch, Dr. med. (1) · David Wyatt, MD (1) · Julia Solnier, PhD (1) · Sascha Venturelli, Dr. med. Dr. rer. nat. (1)